Clinical trials
No Disease or Condition is Being Studied clinical trials
Below are recruiting no disease or condition is being studied clinical trials, each written for real people, not researchers. We’re tracking 18,394 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06267183RecruitingEarly Phase 1
Safety study of a new drug in healthy volunteers
This study tests a new investigational drug called SV001 in healthy volunteers to see if it is safe and how the body handles it. It is a first-in-human trial, meaning this drug has not been tested in people before.
ShanghaiAges 18–45 - NCT06257355RecruitingPhase 1
Testing a new eye drop for corneal scars
This trial tests a new eye drop to see if it can safely and effectively reduce corneal scars. It is for people who have a recent corneal injury (within the last month) that resulted in a scar that affects their vision.
Loma Linda, CaliforniaAges 18–80 - NCT06265727RecruitingPhase 1/Phase 2
Study of CRB-701 for solid tumors with nectin-4
This trial tests a new drug, CRB-701, for people with advanced solid tumors that have a protein called nectin-4 on their surface. It might be an option if other treatments have stopped working or are not available.
Birmingham, AlabamaAges 18 years+ - NCT06263231RecruitingPhase 3
Study of INT230-6 injection for soft tissue sarcoma
This study tests an experimental drug, INT230-6, injected directly into tumors, compared to the usual treatments for soft tissue sarcoma. It aims to see if the injection is safe and works better for people whose cancer has not responded to earlier treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT06266299RecruitingPhase 1
Study of KK2269 for adults with solid tumors
This trial tests a new drug called KK2269 for adults with solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective, possibly as a treatment option for certain cancers like lung or stomach cancer.
Scottsdale, ArizonaAges 18 years+ - NCT06267729RecruitingPhase 1/Phase 2
A new cell therapy for advanced prostate cancer
This trial tests a new cell therapy (AZD0754) for metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It’s looking for people whose cancer has gotten worse despite prior treatments, and who are still in fairly good health.
Duarte, CaliforniaAges 18–130 - NCT06256575Recruiting
Diosmin for healing finger ulcers in scleroderma
This study tests whether a natural supplement called diosmin can help heal finger and toe ulcers in people with scleroderma. If you have a current ulcer that is not infected, you may be able to join.
Calgary, AlbertaAges 18 years+ - NCT06260514RecruitingPhase 1
New drug APR-1051 for advanced solid tumors
This trial tests a new drug called APR-1051 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this drug is safe and effective.
New Brunswick, New JerseyAges 18 years+ - NCT06274515RecruitingPhase 4
Study of resistance to breast cancer therapies
This study looks at why some breast cancers stop responding to treatment. It involves taking a small sample of your tumor (biopsy) and blood to understand resistance. If you have HER2-positive or triple-negative breast cancer that is growing despite treatment, you may be able to join.
AnderlechtAges 18 years+ - NCT06256588RecruitingPhase 3
Dostarlimab vs placebo after chemoradiation for head and neck cancer
This study tests whether the immunotherapy drug dostarlimab, given after standard chemoradiation, can keep advanced head and neck cancer from coming back. It is for people who have not had surgery and whose tumors are PD-L1 positive.
Jonesboro, ArkansasAges 18 years+ - NCT06253130RecruitingPhase 1/Phase 2
Study of IMP1734 for Advanced Solid Tumors with HRR Mutations
This trial tests a new drug called IMP1734 for people with advanced breast, ovarian, or prostate cancer that has a specific genetic change called an HRR mutation. The drug targets a protein called PARP1 to try to stop cancer cells from repairing themselves.
Tucson, ArizonaAges 18–89 - NCT06271265RecruitingPhase 1
Testing EXPAREL for pain after heart surgery in children
This study tests a long-acting pain medicine (EXPAREL) given during heart surgery to see how it works in young children. The goal is to help control pain after surgery with fewer side effects.
Indianapolis, IndianaAges birth–6 years - NCT03650673Recruiting
Study of early finger osteoarthritis symptoms over time
This study follows people with early finger (hand) osteoarthritis symptoms to better understand how the condition starts and changes. You may be asked for blood tests, symptom checks, and imaging to see what’s happening in the joints.
MontpellierAges 18–60 - NCT05412927Recruiting
Heart device follow-up study for high-risk heart patients
This study monitors how well the AngelMed Guardian® System works after it has already been implanted. It focuses on people at higher risk of heart events, including those with diabetes or kidney problems.
Glendale, ArizonaAges 21 years+ - NCT06128278RecruitingPhase 2
Equol supplement and blood vessel health in women
This study tests whether taking an Equol supplement (a soy-related compound) improves blood vessel function in postmenopausal women with and without chronic kidney disease (CKD). It could help women with or without early-stage CKD learn if this supplement supports heart health.
Aurora, ColoradoAges 50–69 - NCT06240221Enrolling by invitation
Tracking real-world use of the Saber-C cervical fusion device
This registry tracks how the Saber-C implant works in real-life neck surgeries. It gathers information to help doctors understand outcomes for people like you.
Paducah, KentuckyAges 18 years+ - NCT06247787RecruitingPhase 1
Imetelstat plus chemo for relapsed leukemia in kids
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
Birmingham, AlabamaAges 1–18 - NCT06230887Enrolling by invitation
New treatment for moral injury in veterans
This study tests a new therapy for veterans struggling with moral injury—distress from events that go against personal values. It compares two treatment approaches to see which works better.
Little Rock, ArkansasAges 18 years+ - NCT06244199Recruiting
Transition to cardiac rehabilitation for veterans with heart disease
This study tests a program that helps Veterans with heart disease start cardiac rehabilitation (a supervised exercise and education program to improve heart health) while they are still in the hospital. It aims to overcome barriers like other health problems and frailty, and may add up to 2 days to your hospital stay.
Boston, MassachusettsAges 18 years+ - NCT06246123Recruiting
Jyseleca tablet safety study in Korean patients
This study tracks Korean patients already taking Jyseleca for rheumatoid arthritis or ulcerative colitis, making sure it's safe and working as expected. It's not testing a new drug, just watching how patients do over time.
Cheonan, Chungcheongnam-doAges 18 years+ - NCT06243354RecruitingPhase 1/Phase 2
Study of HYP-2090PTSA for KRAS-mutated advanced solid tumors
This trial tests a new targeted pill called HYP-2090PTSA for people with advanced solid tumors that have a specific KRAS mutation. The goal is to see if the drug can shrink tumors or slow their growth.
Fuzhou, FujianAges 18 years+ - NCT06235229RecruitingPhase 1/Phase 2
GC012F for relapsed/refractory multiple myeloma
This trial tests a new CAR-T cell therapy called GC012F for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this treatment can help control the disease.
BeijingAges 18–75 - NCT06233942RecruitingPhase 1
Testing a new drug for advanced solid tumors
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Los Angeles, CaliforniaAges 18 years+
Hear when a new No Disease or Condition is Being Studied trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for no disease or condition is being studied?
- Yes. Clin2 currently lists 18,394 recruiting no disease or condition is being studied studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a no disease or condition is being studied trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a no disease or condition is being studied trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.